Form 4 for ZNTL Zentalis Pharmaceuticals, Inc.
Accepted 2023-03-02 00:00:00 ET · period of report 2023-03-01 · accession 0001725160-23-000050 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-02 | 2023-03-01 | ZNTL | Roth Iris | COO | A - Grant | $0.00 | +52.5K | 52.5K | New | $0 |
| D | 2023-03-02 | 2023-03-01 | ZNTL | Roth Iris | COO | A - Grant | $0.00 | +297.5K | 297.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-01 | A | A | 52,500 | $0.00 | 52,500 | D | — | — | (F1) Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the vesting commencement date of Feb. 6, 2023, subject to the Reporting Person's continuing service with the Issuer. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-03-01 | A | A | 297,500 | $0.00 | 297,500 | D | $18.87 · — to 2033-03-01 | 297,500 Common Stock | (F2) The options will vest over four years: 25% of the options will vest on February 6, 2024, with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer. |